Process validation should begin during process design, when you can still learn how materials, equipment, methods, and operating ranges affect product quality without paying commercial-scale costs. Early process validation turns the qualification run into confirmation of process knowledge rather than the first serious test of it.
A failed Process Performance Qualification (PPQ) batch rarely begins failing on the day it enters manufacturing. Its root causes often trace back to development decisions, weak process knowledge, untested operating ranges, or scale-up assumptions made months earlier.
Starting validation work sooner helps you identify variability before it becomes a deviation, failed batch, delayed transfer, or regulatory concern. It also gives your engineering, quality, manufacturing, and Research and Development (R&D) teams a shared body of evidence for making better decisions.
Why Is the Final Gate View of Validation So Costly?
Treating validation as a final gate postpones process learning until changes are harder and more expensive to make. By the time PPQ begins, materials may be committed, equipment selected, procedures approved, and production schedules fixed.
The final-gate view often reduces validation to a set of qualification batches that must pass before launch. That mindset encourages teams to focus on producing acceptable results rather than proving that the process operates predictably across justified ranges. A passing batch provides limited assurance if the team can’t explain why it passed or which variables could cause the next batch to fail.
When a PPQ run produces an out-of-specification (OOS) result, the immediate costs can include lost material, investigation work, laboratory testing, equipment time, and schedule disruption. The wider cost comes from reopening development questions that should have been addressed earlier. Your team may need to revise procedures, reassess limits, repeat training, or conduct additional qualification work under launch pressure.
At What Stage of Development Should Process Validation Begin?
Process validation should begin in Stage 1 Process Design, during laboratory and development work. You don’t need a locked commercial process to start building the evidence that later supports qualification.
Early work should examine how input materials, process settings, equipment choices, sampling methods, and environmental conditions affect output quality. Design of Experiments (DoE) can help you assess several variables together instead of changing one factor at a time. Risk assessments can then focus resources on variables with the strongest connection to product quality and process consistency.
Starting early doesn’t mean freezing every setting or imposing narrow limits before enough data exists. It means documenting what you know, what remains uncertain, and how you plan to close those knowledge gaps. Development ranges can remain broad when evidence supports them, then become more defined as scale-up and process knowledge improve.
How Does the Food and Drug Administration Define the Validation Lifecycle?
The United States Food and Drug Administration (FDA) divides process validation into three connected stages: Process Design, Process Qualification, and Continued Process Verification. This lifecycle model places validation work well before the final PPQ campaign.
Stage 1 establishes the commercial process from knowledge gained through development and scale-up. Stage 2 evaluates whether the process design and manufacturing system can support reproducible commercial production. PPQ sits within this stage, but it depends on the evidence, controls, and scientific reasoning produced earlier.
Stage 3, Continued Process Verification (CPV), uses routine manufacturing data to confirm that the process remains controlled. The International Council for Harmonisation (ICH) Q8 pharmaceutical development guidance supports Quality by Design (QbD), including an understanding of product attributes, process variables, variability, and justified operating ranges. Taken together, these lifecycle principles make the development history part of your validation evidence rather than background material that can be set aside.
Which Process Parameters Should You Study Before Scale-Up?
You should study parameters that can affect product performance, product quality, process consistency, or the ability to maintain control at a larger scale. These become Critical Process Parameters (CPPs) when their variability can affect a Critical Quality Attribute (CQA).
Your assessment may cover mixing time, temperature, pressure, flow rate, hold time, equipment speed, material properties, or other product-specific variables. The right set depends on the process rather than a standard checklist. You need evidence connecting each selected parameter to an identified quality risk, along with a reason for the proposed operating range.
Scale-up can change heat transfer, mixing behavior, equipment geometry, material movement, and measurement capability. Data from a laboratory process can’t always be carried directly into a larger manufacturing system. Scale-down models, engineering studies, DoE, and well-planned pilot work help you test those assumptions before PPQ becomes the testing ground.
How Can Process Analytical Technology Support Early Validation?
Process Analytical Technology (PAT) supports early validation by measuring process conditions and quality indicators during operation. It can help you detect variability as it develops instead of relying only on end-product testing.
PAT tools can generate data about how the process responds to changing inputs and operating conditions. That information can support parameter selection, control strategies, development of operating ranges, and decisions about sampling frequency. The value comes from using the measurements to understand and control the process, not from collecting larger volumes of data without a defined purpose.
This capability also supports manufacturing models that depend on steady-state operation and real-time control. Continuous manufacturing places greater emphasis on monitoring process behavior throughout production rather than judging quality only at batch end. When PAT is considered during development, your team can build suitable sensors, sampling points, data handling, and control logic into the process before equipment choices become difficult to change.
How Does Early Validation Improve Technology Transfer?
Early validation improves technology transfer by giving the receiving site documented knowledge about process behavior, known risks, and justified controls. The transfer becomes an evidence-based handoff rather than an attempt to recreate a process from instructions alone.
A manufacturing recipe may state the approved setpoints, but it may not explain why those setpoints were selected or how much variation the process can tolerate. Without that knowledge, the receiving site can struggle when equipment design, raw material characteristics, analytical methods, or operating practices differ. Seemingly minor differences can then produce deviations that the original development team never tested.
A strong transfer package should explain CPPs, CQAs, proven operating ranges, scale-up assumptions, sampling plans, equipment requirements, and unresolved risks. It should also preserve data integrity by maintaining traceable records of development decisions and study results. When the receiving team understands the reasons behind the process controls, it can compare site differences before qualification rather than discover them during a failed run.
What Is the Difference Between Process Validation and Process Verification?
Process validation establishes documented evidence that a process can consistently produce results meeting defined requirements. Process verification uses ongoing data to confirm that the validated process continues to perform as intended.
Validation includes the development knowledge, facility and equipment qualification, PPQ evidence, and control strategy supporting commercial operation. Verification continues after qualification through monitoring, statistical review, deviation trends, quality results, and other routine manufacturing data. CPV is the lifecycle stage that turns this ongoing review into a planned quality activity.
The two activities serve different purposes but remain connected. Weak development work limits what you can learn from later verification because the team may not know which signals matter or how much variation is acceptable. Strong early process validation gives CPV a meaningful baseline and makes changes in performance easier to detect.
What Happens When Teams Wait Until PPQ?
Waiting until PPQ concentrates technical, financial, and scheduling risk into a small number of expensive manufacturing runs. A failure can expose gaps in process design, scale-up, analytical readiness, operator training, equipment capability, or raw material controls.
Late discovery narrows your available responses. A development-stage adjustment may require a modest study, but the same adjustment near qualification can trigger document revisions, new risk assessments, repeated engineering work, retraining, and schedule changes. If the root cause isn’t well understood, your corrective action may address the symptom without reducing the real source of variability.
The “we don’t have time” objection usually treats early validation as extra work. Much of the work already belongs in development; the difference is whether you plan it around process knowledge or postpone it until a batch fails. A risk-based plan lets you direct time toward the variables, unit operations, and scale-up assumptions most likely to affect quality.
Why Should Process Validation Start Early?
- Lower Cost: Finds design flaws before commercial-scale manufacturing.
- Regulatory Alignment: Supports lifecycle validation and ongoing verification.
- Lower Risk: Identifies CPPs during development, not production.
- Faster Launch: Reduces failed batches, investigations, and delays.
Make Validation a Knowledge Milestone
Your PPQ campaign should confirm a process your team already understands, not expose questions that development left unanswered. Start building process knowledge during Stage 1, test scale-up assumptions before transfer, and connect CPPs to the CQAs they can affect. Use development studies, risk assessment, DoE, PAT, and manufacturing data to replace assumptions with evidence. Early process validation doesn’t require you to lock the process too soon; it gives you the evidence needed to choose defensible limits at the right time. When qualification arrives, your team can focus on demonstrating reproducibility rather than solving old development problems under commercial pressure.
References
- Food and Drug Administration: Process Validation, General Principles and Practices
- International Council for Harmonisation Q8 (R2): Pharmaceutical Development
- Food and Drug Administration: Process Analytical Technology Guidance
- Food and Drug Administration: Quality Considerations for Continuous Manufacturing
- International Society for Pharmaceutical Engineering: Process Validation
- Parenteral Drug Association: Technical Resources.
Nirdosh Jagota is Managing Partner at GRQ Biotech Advisors with 30+ years in the biotech industry. A former executive at Amgen, Genentech/Roche, Merck, and Pfizer, he has led >25 NDAs/BLAs/MAAs and hundreds of INDs across global regulatory, quality, and compliance.